EP0584250A4 - - Google Patents
Info
- Publication number
- EP0584250A4 EP0584250A4 EP19920912707 EP92912707A EP0584250A4 EP 0584250 A4 EP0584250 A4 EP 0584250A4 EP 19920912707 EP19920912707 EP 19920912707 EP 92912707 A EP92912707 A EP 92912707A EP 0584250 A4 EP0584250 A4 EP 0584250A4
- Authority
- EP
- European Patent Office
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US70074091A | 1991-05-15 | 1991-05-15 | |
US700740 | 1991-05-15 |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0584250A1 EP0584250A1 (en) | 1994-03-02 |
EP0584250A4 true EP0584250A4 (cs) | 1994-03-30 |
Family
ID=24814683
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP92912707A Withdrawn EP0584250A1 (en) | 1991-05-15 | 1992-05-14 | Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers |
Country Status (11)
Country | Link |
---|---|
EP (1) | EP0584250A1 (cs) |
JP (1) | JP2930252B2 (cs) |
AU (1) | AU664375B2 (cs) |
CA (1) | CA2103276A1 (cs) |
CZ (1) | CZ281570B6 (cs) |
IE (1) | IE921534A1 (cs) |
IL (1) | IL101858A (cs) |
MX (1) | MX9202243A (cs) |
NZ (1) | NZ242724A (cs) |
WO (1) | WO1992020342A1 (cs) |
ZA (1) | ZA923557B (cs) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3057471B2 (ja) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
JP3883205B2 (ja) * | 1994-03-29 | 2007-02-21 | メルク エンド カンパニー インコーポレーテッド | アンギオテンシン▲ii▼レセプタ遮断イミダゾールによるアテローム性動脈硬化症の治療 |
DE69626958T2 (de) | 1995-03-16 | 2004-03-18 | Pfizer Inc. | Verwendung von amlodipin, eines seiner salze oder felodipin in kombination mit einem ace-hemmer zur herstellung eines arzneimittels zur behandlung von nicht ischämischer kongestiver herzinsuffizienz |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
DE69936992T2 (de) | 1998-07-10 | 2008-03-06 | Novartis Pharma Ag | Bluthochdruckgegenmittelkombination des valsartan und kalziumkanal blocker |
US7481803B2 (en) * | 2000-11-28 | 2009-01-27 | Flowmedica, Inc. | Intra-aortic renal drug delivery catheter |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
JP4000505B2 (ja) * | 1999-12-01 | 2007-10-31 | 第一三共株式会社 | 緑内障を治療するための併用剤 |
GB0008332D0 (en) * | 2000-04-04 | 2000-05-24 | Pfizer Ltd | Treament |
WO2001082858A2 (de) * | 2000-05-04 | 2001-11-08 | Ipf Pharmaceuticals Gmbh | Neue verbindungen zur behandlung inflammatorischer und kardiovaskulärer erkrankungen |
CA2430924A1 (en) * | 2000-12-01 | 2002-06-06 | Novartis Ag | Angiotensin receptor antagonist composition for the treatment of sexual dysfunction associated with hypertension and another condition |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EP3045174A1 (en) * | 2003-01-31 | 2016-07-20 | Daiichi Sankyo Company, Limited | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
TW200833325A (en) * | 2006-12-26 | 2008-08-16 | Daiichi Sankyo Co Ltd | Pharmaceutical composition comprising ascorbic acid |
WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
AU2009256157B2 (en) | 2008-06-04 | 2014-12-18 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
EP2321341B1 (en) | 2008-07-16 | 2017-02-22 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
AU2014235209B2 (en) | 2013-03-15 | 2018-06-14 | Bausch Health Ireland Limited | Guanylate cyclase receptor agonists combined with other drugs |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0411766A1 (en) * | 1989-07-03 | 1991-02-06 | Merck & Co. Inc. | Substituted quinazolinones as angiotensin II antagonists |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2607004B1 (fr) * | 1986-11-20 | 1990-06-01 | Synthelabo | Compositions pharmaceutiques contenant du diltiazem et un inhibiteur de l'enzyme de conversion de l'angiotensine |
US5015651A (en) * | 1988-01-07 | 1991-05-14 | E. I. Du Pont De Nemours And Company | Treatment of hypertension with 1,2,4-angiotensin II antagonists |
EP0565634B1 (en) * | 1990-12-14 | 1999-03-17 | Smithkline Beecham Corporation | Angiotensin ii receptor blocking compositions |
-
1992
- 1992-05-13 NZ NZ242724A patent/NZ242724A/xx not_active IP Right Cessation
- 1992-05-14 CA CA002103276A patent/CA2103276A1/en not_active Abandoned
- 1992-05-14 EP EP92912707A patent/EP0584250A1/en not_active Withdrawn
- 1992-05-14 WO PCT/US1992/003873 patent/WO1992020342A1/en not_active Application Discontinuation
- 1992-05-14 AU AU20269/92A patent/AU664375B2/en not_active Expired
- 1992-05-14 IL IL10185892A patent/IL101858A/en not_active IP Right Cessation
- 1992-05-14 JP JP5500110A patent/JP2930252B2/ja not_active Expired - Lifetime
- 1992-05-14 CZ CS932351A patent/CZ281570B6/cs not_active IP Right Cessation
- 1992-05-14 MX MX9202243A patent/MX9202243A/es unknown
- 1992-05-15 ZA ZA923557A patent/ZA923557B/xx unknown
- 1992-07-01 IE IE153492A patent/IE921534A1/en not_active Application Discontinuation
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0411766A1 (en) * | 1989-07-03 | 1991-02-06 | Merck & Co. Inc. | Substituted quinazolinones as angiotensin II antagonists |
Non-Patent Citations (2)
Title |
---|
CHIU A.T. ET AL: "Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent", J. PHARMACOL. EXP. THER. (USA), 1990, VOL. 252, NO. 2, PAGE(S) 711-718, * |
See also references of WO9220342A1 * |
Also Published As
Publication number | Publication date |
---|---|
CZ281570B6 (cs) | 1996-11-13 |
AU2026992A (en) | 1992-12-30 |
JPH06508128A (ja) | 1994-09-14 |
AU664375B2 (en) | 1995-11-16 |
IL101858A (en) | 1996-08-04 |
NZ242724A (en) | 1994-09-27 |
JP2930252B2 (ja) | 1999-08-03 |
WO1992020342A1 (en) | 1992-11-26 |
MX9202243A (es) | 1992-11-01 |
CA2103276A1 (en) | 1992-11-16 |
EP0584250A1 (en) | 1994-03-02 |
ZA923557B (en) | 1993-11-15 |
IE921534A1 (en) | 1992-11-18 |
IL101858A0 (en) | 1992-12-30 |
CZ235193A3 (en) | 1994-03-16 |
Similar Documents
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19931116 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 19940208 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE |
|
17Q | First examination report despatched |
Effective date: 19981126 |
|
GRAG | Despatch of communication of intention to grant |
Free format text: ORIGINAL CODE: EPIDOS AGRA |
|
RTI1 | Title (correction) |
Free format text: COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Withdrawal date: 20010301 |